ARS Pharmaceuticals, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
ARS Pharmaceuticals, Inc. (SPRY) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $1.63 million for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-10.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2025-11-10
- ARS Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00.
- ARS Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-06-30 was $1.53M.
- ARS Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-03-31 was $100.00K.
- ARS Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $0.00.
- ARS Pharmaceuticals, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $3.10M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|---|
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $1.53M derived: sum of 2 quarters · filed 2025-11-10 | $1.63M 10-Q · filed 2025-11-10 | ||
| 2025-06-30 | $1.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $1.63M 10-Q · filed 2025-08-13 | |||
| 2025-03-31 | $100.00K 10-Q · filed 2025-05-14 | ||||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-13 | ||||
| 2021-12-31 | $3.10M 10-K · filed 2022-03-31 | ||||
| 2021-09-30 | $3.10M 10-Q · filed 2021-11-10 | ||||
| 2021-07-01 | $600.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |